熱門資訊> 正文
胰腺治疗数据导致免疫工程股票飙升45%
2024-09-13 05:58
- Immuneering (NASDAQ:IMRX) stock rocketed 45% post-market Thursday after the company reported positive Phase 2a data for its drug candidate IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel as a first-line treatment for pancreatic cancer.
- The drug developer said the study observed complete or partial responses in the first two out of five patients to date, with an overall initial response rate of 40% and disease control rate of 80%, according to a statement.
- Immuneering said it expects to have additional data by the end of the year.
More on Immuneering
- Seeking Alpha’s Quant Rating on Immuneering
- Historical earnings data for Immuneering
- Financial information for Immuneering
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
